This randomized, placebo-controlled trial will enroll approximately 100 mild to moderate COVID-19 patients and 50 healthcare workers across four leading hospitals in Panama, including internationally recognized Gorgas Memorial Institute of Health Studies, which will also serve as the central laboratory for sample analysis.
The treatment arms will assess the efficacy of a five-day, three time per day nasal decolonization protocol in reducing viral load and symptom progression of mild to moderate COVID-19 patients.
The prevention arms will assess Hexagen's ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.
With authorization from Gorgas Memorial Institute of Health Studies, Hospital Santo Tomas, Caja de Seguro Social, Hospital Integral Panamá Solidario, and the Panamanian Department of Health, the trial is slated to begin enrollment immediately with an initial data read out expected February 2021.
After receiving promising data demonstrating Hexagen's efficacy against human coronaviruses, Turn Therapeutics has worked with international researchers to create and execute a protocol that would document clinical improvement in patients, as well as showcase its preventive capabilities in frontline workers when used as an adjunct to personal protective equipment.
Hexagen is not yet authorized for use specifically as a COVID-19 countermeasure, but the company plans to request Emergency Use Authorization from domestic and international health authorities pending the results of this study.
Hexagen is an FDA cleared advanced wound product that has been used at key opinion leading institutions in the United States since 2015.
It is powered by a first of its kind, patented mixing process called Permafusion, which fuses powerful, liquid active ingredients into a lipid-based carrier (petrolatum) without emulsifiers.
Hexagen contains broad-spectrum, liquid antimicrobials with strong antiviral capabilities suspended in petrolatum.
The product maintains a similar weight and feel to topical antibiotics, yet, unlike antibiotics, Hexagen has shown no resistance or allergic response in patients.
Turn Therapeutics is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care. The company's proprietary technologies are used by healthcare institutions to care for a variety of skin and wound conditions.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT